This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/projekt/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n18http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F26475821%3A_____%2F13%3A%230000175%21RIV14-MZ0-26475821/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F26475821%3A_____%2F13%3A%230000175%21RIV14-MZ0-26475821
rdf:type
skos:Concept n11:Vysledek
rdfs:seeAlso
http://ar.iiarjournals.org/content/33/8/3397.full.pdf+html
dcterms:description
Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). The role of sequential treatment in NSCLC has not been elucidated yet. We compared the efficacy of second-line pemetrexed followed by third-line erlotinib (P-E) to treatment with the reverse sequence (E-P). We analyzed data of 57 patients with advanced-stage (IIIB/IV) lung adenocarcinoma harboring wild-type epidermal growth factor receptor (EGFR) gene; 31 patients were treated with P-E and 26 patients with the E-P sequence. The median progression-free survival (PFS) for patients treated with P-E was 3.6 months vs. 7.8 months for patients treated with E-P (p=0.029). The median overall survival (OS) for patients treated with P-E was 7.9 months vs. 26.3 months for patients treated with E-P (p=0.006). The results proved a significant improvement of both PFS and OS for patients treated with the E-P sequence as compared to the P-E sequence. Pemetrexed and erlotinib represent novel agents for the treatment of non-small cell lung cancer (NSCLC). The role of sequential treatment in NSCLC has not been elucidated yet. We compared the efficacy of second-line pemetrexed followed by third-line erlotinib (P-E) to treatment with the reverse sequence (E-P). We analyzed data of 57 patients with advanced-stage (IIIB/IV) lung adenocarcinoma harboring wild-type epidermal growth factor receptor (EGFR) gene; 31 patients were treated with P-E and 26 patients with the E-P sequence. The median progression-free survival (PFS) for patients treated with P-E was 3.6 months vs. 7.8 months for patients treated with E-P (p=0.029). The median overall survival (OS) for patients treated with P-E was 7.9 months vs. 26.3 months for patients treated with E-P (p=0.006). The results proved a significant improvement of both PFS and OS for patients treated with the E-P sequence as compared to the P-E sequence.
dcterms:title
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence
skos:prefLabel
Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence
skos:notation
RIV/26475821:_____/13:#0000175!RIV14-MZ0-26475821
n11:predkladatel
n16:ico%3A26475821
n3:aktivita
n12:I n12:P
n3:aktivity
I, P(NR9087)
n3:cisloPeriodika
8
n3:dodaniDat
n8:2014
n3:domaciTvurceVysledku
n10:2689677 n10:6636365
n3:druhVysledku
n13:J
n3:duvernostUdaju
n15:S
n3:entitaPredkladatele
n18:predkladatel
n3:idSjednocenehoVysledku
104755
n3:idVysledku
RIV/26475821:_____/13:#0000175
n3:jazykVysledku
n6:eng
n3:klicovaSlova
NSCLC, Pemetrexed, adenocarcinoma, erlotinib, second-line, sequence, third-line
n3:klicoveSlovo
n9:NSCLC n9:erlotinib n9:second-line n9:Pemetrexed n9:sequence n9:adenocarcinoma n9:third-line
n3:kodStatuVydavatele
GR - Řecká republika
n3:kontrolniKodProRIV
[CC105265F81C]
n3:nazevZdroje
Anticancer Research
n3:obor
n17:EB
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
6
n3:projekt
n14:NR9087
n3:rokUplatneniVysledku
n8:2013
n3:svazekPeriodika
33
n3:tvurceVysledku
Benešová, Lucie Minárik, Marek
s:issn
0250-7005
s:numberOfPages
6